# Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study

> **NCT01348282** · PHASE4 · COMPLETED · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 33 (actual)

## Conditions studied

- Neurocognitive Disturbance
- HIV Infection

## Interventions

- **DRUG:** Lithium
- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT01348282
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348282, "Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT01348282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*